OS Therapies (OSTX) Other Non-Current Assets (2025 - 2026)
OS Therapies' (OSTX) quarterly Other Non-Current Assets came in at $6.4 million in Q1 2026, up 4153.26% YoY from $150000.0 in Q1 2025, and down 1.91% on a QoQ basis from $6.5 million in Q4 2025.
OS Therapies (OSTX) Other Non-Current Assets (2025 - 2026) Analysis & Trends
OS Therapies (OSTX) has 2 years of Other Non-Current Assets data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 4153.26% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 4153.26% YoY) and the FY2025 annual result came in at $6.5 million, changed N/A from the prior year.
- Other Non-Current Assets declined to $6.4 million in Q1 2026, from $6.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $6.8 million in Q2 2025 to a low of $150000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | 6.63 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 150,000.00 |